ArticleJournal of clinical pharmacology2021

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing.

Ih Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.